Perrigo Past Earnings Performance
Past criteria checks 0/6
Perrigo's earnings have been declining at an average annual rate of -47.6%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 1.2% per year.
Key information
-47.6%
Earnings growth rate
-47.3%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 1.2% |
Return on equity | -3.2% |
Net Margin | -3.3% |
Last Earnings Update | 28 Sep 2024 |
Recent past performance updates
Recent updates
Is Perrigo (NYSE:PRGO) A Risky Investment?
Dec 06Perrigo Company: Great Combination Of Future Growth With A Low Valuation
Nov 19Perrigo (NYSE:PRGO) Has Announced A Dividend Of $0.276
Nov 07Improved Revenues Required Before Perrigo Company plc (NYSE:PRGO) Shares Find Their Feet
Oct 18Perrigo (NYSE:PRGO) Is Due To Pay A Dividend Of $0.276
Aug 21The Play On Perrigo
Aug 16Perrigo (NYSE:PRGO) Has Announced A Dividend Of $0.276
Aug 07Improved Revenues Required Before Perrigo Company plc (NYSE:PRGO) Shares Find Their Feet
Jul 03These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively
May 29Benign Growth For Perrigo Company plc (NYSE:PRGO) Underpins Its Share Price
Mar 27These 4 Measures Indicate That Perrigo (NYSE:PRGO) Is Using Debt Extensively
Feb 01The Market Doesn't Like What It Sees From Perrigo Company plc's (NYSE:PRGO) Revenues Yet
Dec 28Perrigo's New Chapter: Its Bold Turnaround Plan Is Worth Buying
Nov 15The Prognosis For Perrigo
Aug 30Perrigo Outlook Healed By Repositioning
Jun 12Perrigo raises dividend by 5% to $0.273/share
Feb 21Perrigo: Still Languishing But Short-Term Trend Offers Encouragement
Jan 18Perrigo Non-GAAP EPS of $0.56 misses by $0.11, revenue of $1.1B misses by $40M, lowers FY adj. EPS guidance
Nov 08Perrigo to invest $170M to expand baby formula manufacturing, buys Nestlé Gateway plant
Nov 01Perrigo Company plc Is Back On Track
Oct 20Perrigo to face FDA AdCom meeting for OTC contraceptive
Sep 12Perrigo responds to 'misleading and inaccurate information' on Zantac claims
Aug 17Perrigo reports Q2 mixed results; raises FY22 organic net sales growth outlook
Aug 09Perrigo declares $0.26 dividend
Aug 02Perrigo: HRA Acquisition To Drive Significant Growth
Jul 20Perrigo unit seeks FDA over-the-counter approval for birth control pill Opill
Jul 11Revenue & Expenses Breakdown
How Perrigo makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
28 Sep 24 | 4,392 | -147 | 1,182 | 114 |
29 Jun 24 | 4,428 | -114 | 1,215 | 118 |
30 Mar 24 | 4,556 | 1 | 1,246 | 120 |
31 Dec 23 | 4,656 | -4 | 1,272 | 123 |
30 Sep 23 | 4,654 | 11 | 1,227 | 126 |
01 Jul 23 | 4,630 | -57 | 1,204 | 126 |
01 Apr 23 | 4,559 | -131 | 1,210 | 125 |
31 Dec 22 | 4,452 | -131 | 1,161 | 123 |
01 Oct 22 | 4,401 | -86 | 1,168 | 121 |
02 Jul 22 | 4,344 | -88 | 1,170 | 119 |
02 Apr 22 | 4,203 | -135 | 1,107 | 120 |
31 Dec 21 | 4,139 | -131 | 1,108 | 122 |
02 Oct 21 | 4,087 | -215 | 1,146 | 125 |
03 Jul 21 | 4,047 | -135 | 1,126 | 128 |
03 Apr 21 | 4,015 | -11 | 1,105 | 125 |
31 Dec 20 | 4,088 | 44 | 1,100 | 122 |
26 Sep 20 | 4,358 | 77 | 1,096 | 148 |
27 Jun 20 | 4,546 | 143 | 1,109 | 162 |
28 Mar 20 | 4,746 | 140 | 1,147 | 175 |
31 Dec 19 | 3,870 | 159 | 1,095 | 119 |
28 Sep 19 | 4,710 | 247 | 1,157 | 173 |
29 Jun 19 | 4,652 | 87 | 1,142 | 172 |
30 Mar 19 | 4,689 | 114 | 1,127 | 220 |
31 Dec 18 | 4,732 | 131 | 1,124 | 219 |
29 Sep 18 | 4,820 | 123 | 1,133 | 221 |
30 Jun 18 | 4,918 | 235 | 1,158 | 216 |
31 Mar 18 | 4,969 | 129 | 1,158 | 166 |
31 Dec 17 | 4,946 | 120 | 1,146 | 168 |
30 Sep 17 | 4,994 | -1,313 | 1,161 | 162 |
01 Jul 17 | 5,025 | -2,947 | 1,154 | 174 |
01 Apr 17 | 5,127 | -3,412 | 1,177 | 179 |
31 Dec 16 | 5,281 | -4,013 | 1,206 | 184 |
01 Oct 16 | 5,308 | -2,872 | 1,241 | 189 |
02 Jul 16 | 5,320 | -1,021 | 1,289 | 180 |
02 Apr 16 | 5,395 | -509 | 1,313 | 196 |
31 Dec 15 | 5,015 | -2 | 1,144 | 186 |
26 Sep 15 | 4,997 | 144 | 912 | 193 |
27 Jun 15 | 4,227 | 136 | 742 | 188 |
28 Mar 15 | 4,217 | 203 | 591 | 163 |
27 Dec 14 | 4,172 | 347 | 487 | 173 |
27 Sep 14 | 4,079 | 190 | 570 | 157 |
28 Jun 14 | 3,914 | 233 | 566 | 153 |
29 Mar 14 | 3,884 | 192 | 528 | 146 |
28 Dec 13 | 3,800 | 256 | 616 | 129 |
Quality Earnings: PRGO is currently unprofitable.
Growing Profit Margin: PRGO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRGO is unprofitable, and losses have increased over the past 5 years at a rate of 47.6% per year.
Accelerating Growth: Unable to compare PRGO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRGO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: PRGO has a negative Return on Equity (-3.22%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/17 21:27 |
End of Day Share Price | 2024/12/17 00:00 |
Earnings | 2024/09/28 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Perrigo Company plc is covered by 38 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jasper Hellweg | Argus Research Company |
Ishan Majumdar | Baptista Research |
Douglas Tsao | Barclays |